SynthesisBMJ open2015
The effect of statins on average survival in randomised trials, an analysis of end point postponement.
Synthesis in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Pooled it
- Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials.Journal of general internal medicine · 2019Pooled it
- Pooled it
- Trial
- Clinical utility of 1-h post-load glucose in accelerating diagnosis of type 2 diabetes: a prospective cohort study.Acta diabetologica · 2026Article
- Kidney Transplant Outcomes in Patients with and without Type II Diabetes Mellitus.Cardiorenal medicine · 2026Article
- Frailty and Cardiovascular Risk.European cardiology · 2026Review
- Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.Lipids in health and disease · 2023Article
- Review
- Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.JAMA network open · 2022Article
- Article
- Effects of Statins for Secondary Prevention on Functioning and Other Outcomes Among Nursing Home Residents.Journal of the American Medical Directors Association · 2020Article
- Retrospective cohort study of statin therapy effect on resected colorectal liver metastases.World journal of gastrointestinal surgery · 2020Article
- Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.Drug safety · 2018Article
- Review
- Do Statins Have Antidepressant Effects?CNS drugs · 2017Review
- A method of decision analysis quantifying the effects of age and comorbidities on the probability of deriving significant benefit from medical treatments.Journal of comorbidity · 2017Article
- Cholesterol trials and mortality.British journal of clinical pharmacology · 2016Article
- Pharmacology: Statins and persistent ulceration.British dental journal · 2016Article
- Statins and oral ulceration.British dental journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the average postponement of death in statin trials.
settingA systematic literature review of all statin trials that presented all-cause survival curves for treated and untreated.
interventionStatin treatment compared to placebo. PRIMARY OUTCOME MEASURES: The average postponement of death as represented by the area between the survival curves.
results6 studies for primary prevention and 5 for secondary prevention with a follow-up between 2.0 and 6.1 years were identified. Death was postponed between -5 and 19 days in primary prevention trials and between -10 and 27 days in secondary prevention trials. The median postponement of death for primary and secondary prevention trials were 3.2 and 4.1 days, respectively.
conclusionsStatin treatment results in a surprisingly small average gain in overall survival within the trials' running time. For patients whose life expectancy is limited or who have adverse effects of treatment, withholding statin therapy should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.